KZIA
Kazia Therapeutics Limited
Price Chart
Latest Quote
$14.10
+0.52 (+3.83%)
Current Price
| Previous Close | $13.58 |
| Open | $13.70 |
| Day High | $14.42 |
| Day Low | $13.00 |
| Volume | 255,732 |
Stock Information
Note: Financial values converted from AUD to USD
| Shares Outstanding | 11.43M |
| Total Debt | $71K |
| Cash Equivalents | $49.75M |
| Revenue | $1.36M |
| Net Income | $-16.33M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $143.98M |
| EPS (TTM) | $-7.61 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $86.74M |
| Sales | $1.36M |
| Income | $-16.33M |
| Book/sh | $2.95 |
| Cash/sh | $6.08 |
| Employees | 6 |
Financial Ratios
| Quick Ratio | 2.86 |
| Current Ratio | 2.87 |
| Debt/Eq | 0.21 |
Returns & Margins
| ROA | -25.70% |
| ROE | -106.90% |
| Gross Margin | 100.00% |
| Operating Margin | -14641.04% |
Ownership
| Insider Ownership | 20.57% |
| Institutional Ownership | 38.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -804.82 |
| PEG | 1.01 |
| P/S | 75.83 |
| P/B | 4.27 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $28.43 |
Technical Indicators
| SMA20 | $13.59 |
| SMA50 | $13.46 |
| SMA200 | $10.41 |
| RSI | 44.60 |
| ATR | 1.3586 |
| Shares Float | 9.00M |
| Short Float | 4.90% |
| Short Ratio | 2.73 |
| Volatility | 2.14 |
| Rel Volume | 1.10 |
Performance History
| Week | -4.55% |
| Month | -0.16% |
| Quarter | +0.32% |
| 6 Months | +42.69% |
| YTD | +152.00% |
| Year | +63.00% |
| 3 Years | -70.70% |
| 5 Years | -97.26% |
| 10 Years | -96.82% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-09-01 | $12.60 | 243,799 |
| 2026-08-31 | $13.77 | 377,900 |
| 2026-08-28 | $13.58 | 1,179,300 |
| 2026-08-27 | $16.90 | 985,900 |
| 2026-08-26 | $14.60 | 100,700 |
| 2026-08-25 | $13.79 | 92,900 |
| 2026-08-24 | $13.20 | 61,800 |
| 2026-08-21 | $13.41 | 149,000 |
| 2026-08-20 | $13.67 | 99,600 |
| 2026-08-19 | $14.07 | 141,500 |
| 2026-08-18 | $14.38 | 161,700 |
| 2026-08-17 | $13.56 | 115,900 |
| 2026-08-14 | $13.52 | 142,800 |
| 2026-08-13 | $13.21 | 249,800 |
| 2026-08-12 | $12.79 | 256,300 |
| 2026-08-11 | $13.88 | 95,200 |
| 2026-08-10 | $13.95 | 210,900 |
| 2026-08-07 | $13.89 | 295,200 |
| 2026-08-06 | $12.33 | 250,800 |
| 2026-08-05 | $12.00 | 233,000 |
| 2026-08-04 | $12.31 | 152,200 |
| 2026-08-03 | $12.41 | 197,300 |
About Kazia Therapeutics Limited
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
đ° Latest News
Kazia Therapeutics Reports Preclinical Tumor Reduction in Colorectal Cancer Study
MT Newswires âĸ 2026-09-01T12:30:07ZKazia closes oversubscribed offering to fund paxalisibâs clinical development
Pharmaceutical Technology âĸ 2026-09-01T09:52:49Z
Kazia Therapeutics Proposes Tranched Public Offering
MT Newswires âĸ 2026-08-27T21:41:50ZHow Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform
Insider Monkey âĸ 2026-04-28T17:30:13Z
US Equity Futures Mixed Pre-Bell Monday Despite Oil Sector Surge
MT Newswires âĸ 2026-01-05T13:51:33ZTraders Await Nvidia Earnings, Fed Minutes, Driving Narrow Premarket Gains for US Equity Futures
MT Newswires âĸ 2025-11-19T14:08:22Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $29,947 | $1,645,633 | $0 | $0 |
| Operating Revenue | $29,947 | $1,645,633 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $10,166,845 | $21,939,393 | $17,216,399 | $18,109,803 |
| Other Income Expense | $-5,920,142 | $998,930 | $2,415,686 | $10,695 |
| Other Non Operating Income Expenses | $-1,766,845 | $914,082 | $713 | - |
| Net Non Operating Interest Income Expense | $51,337 | $8,556 | $15,686 | $1,426 |
| Operating Expense | $10,166,845 | $21,939,393 | $17,216,399 | $18,109,803 |
| Other Operating Expenses | $-1,274,153 | $-123,351 | $-713 | $-7,130 |
| General And Administrative Expense | $6,217,469 | $9,670,588 | $6,119,786 | $3,645,633 |
| Selling And Marketing Expense | - | $0 | $0 | $90,553 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-14,760,784 | $-19,093,048 | $-14,591,800 | $-17,835,294 |
| Net Interest Income | $51,337 | $8,556 | $15,686 | $1,426 |
| Interest Income | $51,337 | $8,556 | $15,686 | $1,426 |
| Normalized Income | $-10,930,529 | $-19,177,046 | $-16,975,915 | $-17,845,834 |
| Net Income From Continuing And Discontinued Operation | $-14,760,784 | $-19,093,048 | $-14,591,800 | $-17,835,294 |
| Net Income Common Stockholders | $-14,760,784 | $-19,093,048 | $-14,591,800 | $-17,835,294 |
| Net Income | $-14,760,784 | $-19,093,048 | $-14,591,800 | $-17,835,294 |
| Net Income Including Noncontrolling Interests | $-14,760,784 | $-19,093,048 | $-14,591,800 | $-17,835,294 |
| Net Income Continuous Operations | $-14,760,784 | $-19,093,048 | $-14,591,800 | $-17,835,294 |
| Pretax Income | $-16,005,704 | $-19,286,274 | $-14,785,026 | $-18,097,682 |
| Special Income Charges | $-4,153,298 | $84,848 | $2,415,686 | $10,695 |
| Interest Income Non Operating | $51,337 | $8,556 | $15,686 | $1,426 |
| Operating Income | $-10,136,898 | $-20,293,761 | $-17,216,399 | $-18,109,803 |
| Per Share | ||||
| Diluted EPS | $-13.48 | - | $-40.04 | $-66.35 |
| Basic EPS | $-13.48 | - | $-8.02 | $-13.46 |
| Other | ||||
| Tax Effect Of Unusual Items | $-323,042 | $850 | $31,571 | $155 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,317,647 | $-19,045,989 | $-18,299,465 | $-16,787,878 |
| Total Unusual Items | $-4,153,298 | $84,848 | $2,415,686 | $10,695 |
| Total Unusual Items Excluding Goodwill | $-4,153,298 | $84,848 | $2,415,686 | $10,695 |
| Reconciled Depreciation | $665,954 | $1,332,620 | $1,332,620 | $1,332,620 |
| EBITDA (Bullshit earnings) | $-9,470,945 | $-18,961,140 | $-15,883,779 | $-16,777,183 |
| EBIT | $-10,136,898 | $-20,293,761 | $-17,216,399 | $-18,109,803 |
| Diluted Average Shares | $781,378 | - | $1,313,971 | $944,511 |
| Basic Average Shares | $781,378 | - | $1,313,971 | $944,511 |
| Diluted NI Availto Com Stockholders | $-14,760,784 | $-19,093,048 | $-14,591,800 | $-17,835,294 |
| Tax Provision | $-1,244,920 | $-193,226 | $-193,226 | $-262,389 |
| Impairment Of Capital Assets | $9,539,394 | $0 | $0 | - |
| Restructuring And Mergern Acquisition | $-5,386,096 | $-84,848 | $-2,415,686 | $0 |
| Research And Development | $5,223,529 | $12,392,157 | $11,097,326 | $14,380,748 |
| Selling General And Administration | $6,217,469 | $9,670,588 | $6,119,786 | $3,736,185 |
| Other Gand A | $6,217,469 | $9,670,588 | $6,119,786 | $3,645,633 |
| Write Off | - | $0 | $0 | $-10,695 |
| Other Taxes | - | - | $0 | $0 |
| Gain On Sale Of Ppe | - | - | - | - |
Fetched: 2026-08-19
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-6,693,761 | $-18,122,638 | $-3,721,212 | $-616,043 |
| Total Assets | $4,321,569 | $15,390,374 | $20,024,242 | $25,589,304 |
| Total Non Current Assets | $803,565 | $11,008,912 | $12,343,672 | $18,852,049 |
| Non Current Prepaid Assets | $28,520 | $28,520 | $30,660 | $5,205,704 |
| Goodwill And Other Intangible Assets | $775,045 | $10,980,392 | $12,313,012 | $13,646,345 |
| Other Intangible Assets | $775,045 | $10,980,392 | $12,313,012 | $13,646,345 |
| Current Assets | $3,518,003 | $4,381,462 | $7,680,570 | $6,737,255 |
| Prepaid Assets | $355,793 | $3,105,169 | $3,868,806 | $1,452,406 |
| Receivables | $64,171 | $94,831 | $74,866 | $36,364 |
| Other Receivables | $64,171 | $94,831 | $74,153 | $36,364 |
| Cash Cash Equivalents And Short Term Investments | $3,098,039 | $1,181,462 | $3,736,898 | $5,248,485 |
| Cash And Cash Equivalents | $3,098,039 | $1,181,462 | $3,736,898 | $5,248,485 |
| Cash Financial | $3,098,039 | $1,181,462 | $3,736,898 | $5,248,485 |
| Accounts Receivable | - | $0 | $713 | $0 |
| Cash Equivalents | - | - | - | $0 |
| Other Current Assets | - | - | - | - |
| Taxes Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $282,353 | $452,050 | $1,280,570 | $1,312,656 |
| Current Debt And Capital Lease Obligation | $282,353 | $452,050 | $1,280,570 | $1,312,656 |
| Current Debt | $282,353 | $452,050 | $1,280,570 | $1,312,656 |
| Other Current Borrowings | $282,353 | $452,050 | $1,280,570 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $10,240,285 | $22,532,620 | $11,432,442 | $12,559,001 |
| Total Non Current Liabilities Net Minority Interest | $220,321 | $4,139,037 | $6,038,503 | $7,761,854 |
| Non Current Deferred Liabilities | $193,939 | $1,438,859 | $1,632,086 | $1,825,312 |
| Non Current Deferred Taxes Liabilities | $193,939 | $1,438,859 | $1,632,086 | $1,825,312 |
| Current Liabilities | $10,019,964 | $18,393,582 | $5,393,939 | $4,797,148 |
| Other Current Liabilities | $2,245,989 | $6,938,324 | $534,759 | $541,176 |
| Payables And Accrued Expenses | $7,213,547 | $10,742,959 | $3,086,631 | $2,680,214 |
| Payables | $4,024,955 | $3,242,781 | $611,052 | $1,086,631 |
| Accounts Payable | $4,024,955 | $3,242,781 | $611,052 | $1,086,631 |
| Other Non Current Liabilities | - | $2,675,223 | $4,364,349 | $5,853,119 |
| Other Payable | - | - | - | $1,594,296 |
| Equity | ||||
| Common Stock Equity | $-5,918,716 | $-7,142,246 | $8,591,800 | $13,030,303 |
| Total Equity Gross Minority Interest | $-5,918,716 | $-7,142,246 | $8,591,800 | $13,030,303 |
| Stockholders Equity | $-5,918,716 | $-7,142,246 | $8,591,800 | $13,030,303 |
| Gains Losses Not Affecting Retained Earnings | $2,210,339 | $2,477,718 | $2,624,599 | $1,719,786 |
| Retained Earnings | $-96,133,331 | $-82,089,125 | $-63,517,289 | $-48,924,776 |
| Other Equity Interest | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $577,125,643 | $237,326,756 | $162,587,600 | $98,934,312 |
| Share Issued | $577,125,643 | $237,326,756 | $162,587,600 | $98,934,312 |
| Tangible Book Value | $-6,693,761 | $-18,122,638 | $-3,721,212 | $-616,043 |
| Invested Capital | $-5,636,363 | $-6,690,196 | $9,872,371 | $14,342,959 |
| Working Capital | $-6,501,961 | $-14,012,121 | $2,286,631 | $1,940,107 |
| Total Capitalization | $-5,918,716 | $-7,142,246 | $8,591,800 | $13,030,303 |
| Additional Paid In Capital | $270,945 | $0 | $0 | $0 |
| Capital Stock | $87,733,331 | $72,469,160 | $69,484,490 | $60,235,293 |
| Common Stock | $87,733,331 | $72,469,160 | $69,484,490 | $60,235,293 |
| Employee Benefits | $26,381 | $24,955 | $42,068 | $83,422 |
| Pensionand Other Post Retirement Benefit Plans Current | $278,075 | $260,250 | $491,979 | $263,102 |
| Current Accrued Expenses | $3,188,592 | $7,500,178 | $2,475,579 | $1,593,583 |
Fetched: 2026-08-19
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,467,379 | $-6,831,372 | $-10,806,417 | $-16,229,590 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,467,379 | $-6,831,372 | $-10,806,417 | $-16,229,590 |
| Cash Flow From Continuing Operating Activities | $-9,467,379 | $-6,831,372 | $-10,806,417 | $-16,229,590 |
| Operating Gains Losses | $221,034 | $-14,260 | $32,799 | $-1,535,829 |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $0 | $-1,686,274 |
| Cash Flow From Continuing Investing Activities | - | $0 | $0 | $-1,686,274 |
| Net Other Investing Changes | - | - | - | $-1,686,274 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,555,436 | $3,978,610 | $9,249,198 | $2,656,684 |
| Financing Cash Flow | $11,395,365 | $4,267,380 | $9,249,198 | $2,656,684 |
| Cash Flow From Continuing Financing Activities | $11,395,365 | $4,267,380 | $9,249,198 | $2,656,684 |
| Net Common Stock Issuance | $10,555,436 | $3,978,610 | $9,249,198 | $2,656,684 |
| Common Stock Issuance | $10,555,436 | $3,978,610 | $9,249,198 | $2,656,684 |
| Other | ||||
| Repayment Of Debt | $0 | $-264,528 | $0 | $0 |
| Issuance Of Debt | $0 | $553,298 | $0 | $0 |
| End Cash Position | $3,098,039 | $1,181,462 | $3,736,898 | $5,248,485 |
| Beginning Cash Position | $1,181,462 | $3,736,898 | $5,248,485 | $19,669,875 |
| Effect Of Exchange Rate Changes | $-11,408 | $8,556 | $45,633 | $837,790 |
| Changes In Cash | $1,927,986 | $-2,563,993 | $-1,557,219 | $-15,259,180 |
| Proceeds From Stock Option Exercised | $839,929 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $0 | $288,770 | $0 | $0 |
| Net Short Term Debt Issuance | $0 | $288,770 | $0 | $0 |
| Short Term Debt Payments | $0 | $-264,528 | $0 | $0 |
| Short Term Debt Issuance | $0 | $553,298 | $0 | $0 |
| Change In Working Capital | $-2,144,741 | $7,131,551 | $3,088,770 | $614,617 |
| Change In Other Working Capital | $-1,225,668 | $-442,068 | $-4,991 | $-119,073 |
| Change In Other Current Liabilities | $-169,697 | $-828,520 | $-32,086 | $1,312,656 |
| Change In Other Current Assets | $71,301 | $742,246 | $260,250 | $-197,504 |
| Change In Payables And Accrued Expense | $-3,529,412 | $7,656,328 | $405,704 | $-376,471 |
| Change In Payable | $-3,529,412 | $7,656,328 | $405,704 | $-376,471 |
| Change In Receivables | $2,708,734 | $3,565 | $2,459,893 | $-4,991 |
| Changes In Account Receivables | $2,708,734 | $3,565 | $2,459,893 | $-4,278 |
| Other Non Cash Items | $-4,154,011 | $4,345,811 | $-1,495,187 | $108,378 |
| Stock Based Compensation | $465,597 | $380,036 | $826,381 | $1,194,296 |
| Unrealized Gain Loss On Investment Securities | $700,178 | $-914,082 | $0 | $0 |
| Asset Impairment Charge | $9,539,394 | $0 | $0 | - |
| Depreciation Amortization Depletion | $665,954 | $1,332,620 | $1,332,620 | $1,332,620 |
| Depreciation And Amortization | $665,954 | $1,332,620 | $1,332,620 | $1,332,620 |
| Amortization Cash Flow | $665,954 | $1,332,620 | $1,332,620 | $1,332,620 |
| Amortization Of Intangibles | $665,954 | $1,332,620 | $1,332,620 | $1,332,620 |
| Net Foreign Currency Exchange Gain Loss | $221,034 | $-14,260 | $32,799 | $-1,535,829 |
| Net Income From Continuing Operations | $-14,760,784 | $-19,093,048 | $-14,591,800 | $-17,835,294 |
| Change In Prepaid Assets | - | - | $260,250 | $1,115,151 |
| Net Business Purchase And Sale | - | - | - | $-1,686,274 |
| Purchase Of Business | - | - | - | $-1,686,274 |
| Net Investment Purchase And Sale | - | - | - | - |
| Sale Of Investment | - | - | - | - |
Fetched: 2026-08-19